<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01867255</url>
  </required_header>
  <id_info>
    <org_study_id>12-005860</org_study_id>
    <nct_id>NCT01867255</nct_id>
  </id_info>
  <brief_title>Study to Examine the Effect of Gastric Bypass Surgery on Venlafaxine ER Blood Levels</brief_title>
  <official_title>Pharmacokinetic Study Comparing Area Under the Curve for a Single Dose of Venlafaxine ER Pre- and Post-gastric Bypass</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mayo Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mayo Clinic</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to determine whether a significant and predictable change in
      bioavailability of extended-release venlafaxine occurs following Roux-en-Y gastric bypass.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2013</start_date>
  <completion_date type="Actual">March 2015</completion_date>
  <primary_completion_date type="Actual">March 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Venlafaxine levels pre- and post-gastric bypass</measure>
    <time_frame>3 to 4 months</time_frame>
    <description>This study will measure and compare venlafaxine and desvenlafaxine levels in participants before, and again 3 to 4 months after, gastric bypass surgery.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">10</enrollment>
  <condition>Bariatric Surgery</condition>
  <condition>Gastric Bypass</condition>
  <condition>Roux-en-Y Gastric Bypass</condition>
  <arm_group>
    <arm_group_label>venlafaxine ER</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>venlafaxine ER (extended-release) 75 mg once</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>venlafaxine ER (extended-release) 75 mg</intervention_name>
    <description>A single dose of venlafaxine ER 75 mg is to be administered once at each of two study visits, pre- and post-gastric bypass surgery.</description>
    <arm_group_label>venlafaxine ER</arm_group_label>
    <other_name>Effexor XR 75 mg</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

        - Approved to undergo Roux-en-Y gastric bypass surgery (cost of surgery is NOT included in
        the study)

        Exclusion criteria:

          -  Pregnant

          -  Allergy to venlafaxine or desvenlafaxine

          -  Psychiatric hospitalization within the prior 12 months

          -  Active professional treatment for recent substance abuse within 12 months of
             abstinence

          -  Ongoing psychologic issues, such as personality disorders, difficulties as a trauma
             survivor, or difficulties with depression unless a stable, documented course of
             treatment by a licensed mental health professional is available

          -  Current use of any of the following medications/supplements: 5-hydroxytryptophan,
             almotriptan, amitriptyline, amoxapine, amoxicillin-clavulanate,
             amphetamine-dextroamphetamine, atazanavir, bupropion, cinacalcet, citalopram,
             clarithromycin, clomipramine, desipramine, desvenlafaxine, dextroamphetamine,
             dextromethorphan, doxepin, duloxetine, eletriptan, entacapone, escitalopram,
             fluoxetine, fluvoxamine, frovatriptan, haloperidol, imipramine, isocarboxazid,
             itraconazole, jujube seed extract, linezolid, maprotiline, methylene blue,
             metoclopramide, metoprolol, milnacipran, mirtazapine, naratriptan, nefazodone,
             nelfinavir, nortriptyline, paroxetine, phenelzine, procarbazine, protriptyline,
             quinidine, rasagiline, ritonavir, rizatriptan, saquinavir, selegiline, sertraline, St.
             John's wort, sumatriptan, tapentadol, terbinafine, toremifene, tramadol,
             tranylcypromine, trazodone, trifluoperazine, trimipramine, tryptophan, L-tryptophan,
             venlafaxine, vilazodone, zolmitriptan
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Carrie Krieger, PharmD, RPh</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mayo Clinic in Rochester</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 29, 2013</study_first_submitted>
  <study_first_submitted_qc>May 29, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 3, 2013</study_first_posted>
  <last_update_submitted>December 21, 2015</last_update_submitted>
  <last_update_submitted_qc>December 21, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 23, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Mayo Clinic</investigator_affiliation>
    <investigator_full_name>Carrie A. Krieger</investigator_full_name>
    <investigator_title>PharmD, BCACP</investigator_title>
  </responsible_party>
  <keyword>venlafaxine</keyword>
  <keyword>Effexor</keyword>
  <keyword>antidepressive agent</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Venlafaxine Hydrochloride</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

